SCHEDULE: GordonMD Discloses 7.0% Stake in Kyverna Therapeutics

GordonMD Global Investments and related entities report a 7.0% beneficial ownership stake in Kyverna Therapeutics, Inc. common stock.

Summary

• GordonMD Global Investments LP, GordonMD Global Investments GP LLC, and Craig D. Gordon collectively reported beneficial ownership of 3,058,485 shares of Kyverna Therapeutics, Inc. common stock, representing 7.0% of the class.
• GordonMD Long Biased Master Fund LP and GordonMD Long Biased GP LLC reported beneficial ownership of 2,735,783 shares of Kyverna Therapeutics, Inc. common stock, representing 6.2% of the class.
• The reporting persons share both voting and dispositive power over the reported shares.
• The securities were acquired and are held for investment purposes and not with the intent to change or influence control of Kyverna Therapeutics, Inc.

Sentiment

Score: 5

Explanation: The filing is a routine beneficial ownership disclosure (Schedule 13G) and does not contain information that inherently suggests a positive or negative sentiment regarding the issuer's operational or financial performance. It simply reports a significant passive investment.

Future Outlook

The filing does not contain any forward-looking statements or guidance from Kyverna Therapeutics, Inc. or the reporting persons regarding the issuer's future performance.

Management Comments

• The reporting persons certify that, to the best of their knowledge and belief, the securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer, nor were they acquired or held in connection with any transaction having that purpose or effect, other than activities solely in connection with a nomination under Rule 14a-11.

Industry Context

This filing indicates increased institutional interest in Kyverna Therapeutics, Inc., a common occurrence in the biotechnology and pharmaceutical sectors as companies progress through clinical development and commercialization stages. Significant institutional ownership can signal confidence in a company's long-term prospects.

Related Party Transactions

• All reported securities are directly owned by advisory clients of GordonMD Global Investments LP. GordonMD Long Biased Master Fund LP is identified as an advisory client that beneficially owns more than 5% of the common stock.

Stakeholder Impact

• Shareholders may view the significant stake by GordonMD Global Investments as a positive signal of institutional confidence in Kyverna Therapeutics, potentially influencing market perception and liquidity.

Key Dates

Keywords

Kyverna Therapeutics, GordonMD Global Investments, Schedule 13G, beneficial ownership, institutional investment, common stock